Sirexatamab Biosimilar - Research Grade

Product Code: ICH5276

More Information

Species Reactivity: Human

Target: DKK1

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Sirexatamab Biosimilar - Research Grade

Sequence: https://www.imgt.org/mAb-DB/

Buffer: ICH3002

UniProt: O94907

Shipping Conditions: Blue ice

background: This product is a research-grade biosimilar of sirexatamab, supplied as an unconjugated, non-therapeutic analog built around the DKK1 target. It is intended for research use only and is not a clinical drug. The molecule reproduces the target-binding specificity of the originator antibody in a human IgG4 kappa framework, making it suitable as a reference or tool reagent for investigators studying DKK1 biology and DKK1-directed antibody function. Sirexatamab (also known in the literature as DKN-01) is an antibody directed against Dickkopf-related protein 1 (DKK1), a secreted modulator of Wnt signaling implicated in oncology and bone biology. Because it is provided as a bulk, low-endotoxin research reagent rather than a formulated therapeutic, it is well suited to in-vitro and functional characterization work, assay standardization, and comparator studies. As with all biosimilar reference reagents offered here, the emphasis is on consistent target binding and lot quality for experimental use. Investigators should confirm suitability for their specific assay format before proceeding, and treat all guidance as starting points for optimization in

their own systems. DKK1 (Dickkopf-related protein 1, UniProt O94907) is a secreted glycoprotein and a principal antagonist of the canonical Wnt/beta-catenin signaling pathway. It acts primarily by binding the Wnt co-receptor LRP5/LRP6, and in concert with Kremen proteins promotes receptor internalization, thereby dampening Wnt-driven transcription. Through this activity DKK1 helps regulate embryonic patterning, stem-cell maintenance, and bone remodeling, where it restrains osteoblast activity. DKK1 is frequently dysregulated in cancer, where it can influence tumor cell behavior and the surrounding immune microenvironment, and elevated levels have been associated with poor outcomes in several tumor types. Its role at the interface of Wnt signaling, bone metabolism, and tumor-immune crosstalk makes DKK1 an attractive target for antibody-based intervention, which is the biological rationale underlying sirexatamab-class molecules that neutralize DKK1 to modulate downstream Wnt and immune effects.

Other names: Dickkopf-1, hDkk-1, SK, Dickkopf-related protein 1

Specificity: Detects human DKK1

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks